Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0483
Yuqiu Xu, Yang Lv, Zhehui Zhu, Yijiao Chen, Peiwen Zhou, Lechi Ye, Wentao Tang, Jianmin Xu
{"title":"Precision medicine in the treatment of colorectal cancer with liver metastases.","authors":"Yuqiu Xu, Yang Lv, Zhehui Zhu, Yijiao Chen, Peiwen Zhou, Lechi Ye, Wentao Tang, Jianmin Xu","doi":"10.20892/j.issn.2095-3941.2023.0483","DOIUrl":"10.20892/j.issn.2095-3941.2023.0483","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0435
Liwei An, Yi Han, Shi Jiao, Zhaocai Zhou
{"title":"Road of no return - loss of TP53 paves a defined evolution path from gastric preneoplasia-to-cancer.","authors":"Liwei An, Yi Han, Shi Jiao, Zhaocai Zhou","doi":"10.20892/j.issn.2095-3941.2023.0435","DOIUrl":"10.20892/j.issn.2095-3941.2023.0435","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0490
Catalina Amador, Wing C Chan
{"title":"Nodal peripheral T-cell lymphomas in the new classification systems.","authors":"Catalina Amador, Wing C Chan","doi":"10.20892/j.issn.2095-3941.2023.0490","DOIUrl":"10.20892/j.issn.2095-3941.2023.0490","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.
Methods: This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive.
Results: Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (n = 99) and PSA (n = 131) were -401.0 ng/dL [308.4 ng/dL (-462.5, -339.5 ng/dL)] and -35.4 ng/mL [104.4 ng/mL (-53.5, -17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA.
Conclusions: Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.
{"title":"Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.","authors":"Nanhui Chen, Zengjun Wang, Ming Chen, Qi Ma, Yi He, Yujie Wang, Xin Li, Mingxing Qiu, Lei Shi, Shaoxing Zhu, Qun Xie, Xiuheng Liu, Benkang Shi, Guowen Lin, Weizhong Yang, Yongbin Liao, Haibin Zhang, Shusheng Wang, Jiexian Li, Shaogang Wang, Lijun Dong, Hui Chen, Jiaju Lu, Yongyi Cheng, Xiaoping Zhang, Lulin Ma, Liqun Zhou, He Wang, Shen Li, Dingwei Ye","doi":"10.20892/j.issn.2095-3941.2023.0335","DOIUrl":"10.20892/j.issn.2095-3941.2023.0335","url":null,"abstract":"<p><strong>Objective: </strong>Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particularly the long-acting 10.8-mg depot formulation, and the follow-up patterns among Chinese prostate cancer patients.</p><p><strong>Methods: </strong>This was a multicenter, prospective, observational study in hormone treatment-naïve patients with localized or locally advanced prostate cancer who were prescribed goserelin 10.8-mg depot every 12 weeks or 3.6-mg depot every 4 weeks with or without an anti-androgen. The patients had follow-up evaluations for 26 weeks. The primary outcome was the effectiveness of goserelin in reducing serum testosterone and prostate-specific antigen (PSA) levels. The secondary outcomes included testosterone and PSA levels, attainment of chemical castration (serum testosterone <50 ng/dL), and goserelin safety. The exploratory outcome was the monitoring pattern for serum testosterone and PSA. All analyses were descriptive.</p><p><strong>Results: </strong>Between September 2017 and December 2019, a total of 294 eligible patients received ≥ 1 dose of goserelin; 287 patients (97.6%) were treated with goserelin 10.8-mg depot. At week 24 ± 2, the changes from baseline [standard deviation (95% confidence interval)] in serum testosterone (<i>n</i> = 99) and PSA (<i>n</i> = 131) were -401.0 ng/dL [308.4 ng/dL (-462.5, -339.5 ng/dL)] and -35.4 ng/mL [104.4 ng/mL (-53.5, -17.4 ng/mL)], respectively. Of 112 evaluable patients, 100 (90.2%) achieved a serum testosterone level < 50 ng/dL. Treatment-emergent adverse events (TEAEs) and severe TEAEs occurred in 37.1% and 10.2% of patients, respectively. The mean testing frequency (standard deviation) was 1.6 (1.5) for testosterone and 2.2 (1.6) for PSA.</p><p><strong>Conclusions: </strong>Goserelin 10.8-mg depot effectively achieved and maintained castration and was well-tolerated in Chinese patients with localized and locally advanced prostate cancer.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0443
Xianchun Gao, Hui Liu, Jun Yu, Yongzhan Nie
{"title":"DNA methylation biomarkers for early detection of gastric and colorectal cancers.","authors":"Xianchun Gao, Hui Liu, Jun Yu, Yongzhan Nie","doi":"10.20892/j.issn.2095-3941.2023.0443","DOIUrl":"10.20892/j.issn.2095-3941.2023.0443","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0454
Canbin Fang, Xueqi Fan, Wanling Lin, Guojun Zhang
{"title":"Insight into the evolution of breast cancer driven by genetic alterations.","authors":"Canbin Fang, Xueqi Fan, Wanling Lin, Guojun Zhang","doi":"10.20892/j.issn.2095-3941.2023.0454","DOIUrl":"10.20892/j.issn.2095-3941.2023.0454","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-05DOI: 10.20892/j.issn.2095-3941.2023.0402
Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng
Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.
{"title":"Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?","authors":"Lin Ma, Liufu Deng, Jianfeng Peng, Jinming Yu, Xiangjiao Meng","doi":"10.20892/j.issn.2095-3941.2023.0402","DOIUrl":"10.20892/j.issn.2095-3941.2023.0402","url":null,"abstract":"<p><p>Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"20 12","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号